GREY:BIOAF - Post by User
Comment by
prophetoffactzon Jun 09, 2023 3:18pm
257 Views
Post# 35489056
RE:RE:RE:New Questions
RE:RE:RE:New Questions"Well, a LinkedIn post! What better evidence would one want?"
Linkedin like a cherry on top:
1) J&J signed the multi-product option deal.
2) Midatech's CEO hyped BTI's xB3 partnerships and Armistice Capital agreed to finance the BTI/Midatech merger. Ladenberg Thalmann was involved. The merger only tried to raise US$10 million and I believe they expected additional funding from deals to strengthen the cash runway.
3) J&J extended, expanded, and paid a small milestone for its xB3 option deal signifying success.
4) Chiesi, Neuramedy, and Prothena signed an xB3 deal, etc., so xB3 deals aren't without precedent.
5) I believe the Chiesi deal is still active suggesting advancement of xB3(no roadblocks).
6) Rathjen has liked a J&J post and there are likes from J&J at an important time in the option agreement. The liked BTI post affirmed xB3's science.
7) We should see a 'Saltarelli' - a deal consistent with his success and the exercise of the J&J option would be consistent with this.
8) BTI has been waiting for something it appears. The J&J expiry was originally Jan 31. 2023. We are overdue.